(Reuters) -Swiss contract drug manufacturer Lonza reported a rise in its half-year core earnings on Wednesday, beating market expectations, aided by contributions from its Vacaville site in the U.S and strong performance in the mammalian, bioconjugates and small molecules technology platforms.
Lonza reported earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.1 billion Swiss francs ($1.39 billion) for the first six months of 2025, compared with 893 million francs in the same period last year.
Analysts polled by Vara Research had forecast a core profit of 993 million francs.
($1 = 0.7936 Swiss francs)
(Reporting by Isabel Demetz and Bernadette Hogg in Gdansk, editing by Milla Nissi-Prussak)
Comments